FRAZER, Pa., June 17 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that the U.S. Patent and Trademark Office has issued
a pharmaceutical formulation patent for AMRIX(R) (Cyclobenzaprine
Hydrochloride Extended-Release Capsules). U.S. Patent No. 7,387,793 was
issued to Eurand Inc., the developer of AMRIX, and expires on February 26,
2025. Last year, Cephalon acquired an exclusive license from Eurand to
market AMRIX in North America. The issued claims cover Eurand's proprietary
Diffucaps(R) technology used to formulate AMRIX as an extended-release
capsule containing the muscle relaxant cyclobenzaprine. The AMRIX
formulation allows, for the first time, a full day of cyclobenzaprine in a
single dose medication for the treatment of acute painful musculoskeletal
conditions.
"The issuance of this patent supports our investment in AMRIX and its
innovative technology, which offers the only once-daily treatment option
for patients suffering from acute muscle spasms," said Frank Baldino, Jr.,
Ph.D., Chairman and Chief Executive Officer. "Physician and patient
response to AMRIX has resulted in strong prescription growth in 2008 and we
expect that this product will be a key growth driver in our business for
many years."
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of
innovative products in four core therapeutic areas: central nervous system,
pain, oncology and addiction. A member of the Fortune 1000, Cephalon
currently employs approximately 3,000 people in the United States and
Europe. U.S. sites include the company's headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. The company's European headquarters are located in
Maisons-Alfort, France.
The company's proprietary products in the United States include:
TREANDA(R) (bendamustine hydrochloride) for injection, AMRIX, PROVIGIL(R)
(modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II],
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for
extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral
transmucosal fentanyl citrate) [C-II]. The company also markets numerous
products internationally. Full prescribing information on its U.S. products
is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs; development of potential pharmaceutical
products; interpretation of clinical results; manufacturing development and
capabilities; market prospects for its products, including AMRIX; sales and
earnings guidance; and other statements regarding matters that are not
historical facts, including statements regarding the AMRIX patent. You may
identify some of these forward-looking statements by the use of words in
the statements such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe" or other words and terms of similar meaning.
Cephalon's performance and financial results could differ materially from
those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries as well as more specific risks
and uncertainties facing Cephalon such as those set forth in its reports on
Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements. Furthermore,
Cephalon does not intend to update publicly any forward-looking statement,
except as required by law. The Private Securities Litigation Reform Act of
1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
http://www.prnewswire.com/comp/134563.html/
CONTACT:
Media, Sheryl Williams, +1-610-738-6493,
swilliam@cephalon.com; or Investors, Robert (Chip) Merritt,
+1-610-738-6376, cmerritt@cephalon.com, both of Cephalon, Inc.
|
